https://www.mereobiopharma.com/ 2026-03-06 weekly 0.5 https://www.mereobiopharma.com/our-pipeline/ 2026-01-13 weekly 0.5 https://www.mereobiopharma.com/our-pipeline/setrusumab-ux-143/ 2026-01-06 weekly 0.5 https://www.mereobiopharma.com/our-pipeline/alvelestat-mph966/ 2025-12-02 weekly 0.5 https://www.mereobiopharma.com/our-pipeline/other-programs/ 2025-12-10 weekly 0.5 https://www.mereobiopharma.com/investors/ 2026-03-19 weekly 0.5 https://www.mereobiopharma.com/investors/share-information-and-sec-filings/ 2026-03-19 weekly 0.5 https://www.mereobiopharma.com/investors/corporate-governance/ 2026-03-10 weekly 0.5 https://www.mereobiopharma.com/investors/results-presentations/ 2026-01-14 weekly 0.5 https://www.mereobiopharma.com/patient-communities/ 2025-11-21 weekly 0.5 https://www.mereobiopharma.com/patient-communities/oi-community/ 2025-12-11 weekly 0.5 https://www.mereobiopharma.com/patient-communities/alpha-1-community/ 2025-12-11 weekly 0.5 https://www.mereobiopharma.com/patient-communities/rare-disease-day-2025/ 2025-12-02 weekly 0.5 https://www.mereobiopharma.com/patient-communities/rare-disease-day-2024/ 2025-12-02 weekly 0.5 https://www.mereobiopharma.com/hcps/ 2025-11-21 weekly 0.5 https://www.mereobiopharma.com/hcps/osteogenesis-imperfecta/ 2026-01-20 weekly 0.5 https://www.mereobiopharma.com/hcps/alpha-1-antitrypsin-deficiency/ 2025-11-25 weekly 0.5 https://www.mereobiopharma.com/contact-us/ 2026-03-25 weekly 0.0 https://www.mereobiopharma.com/news/ 2026-03-19 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-first-quarter-2025-financial-results-and-provides-corporate-highlights/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-to-participate-in-fireside-chat-at-the-jefferies-global-healthcare-conference-2025/ 2025-10-21 weekly 0.5 https://www.mereobiopharma.com/news/mereo-to-present-at-jp-morgan-healthcare-conference/ 2025-10-21 weekly 0.5 https://www.mereobiopharma.com/news/update-on-lead-clinical-programs/ 2025-09-15 weekly 0.5 https://www.mereobiopharma.com/news/full-year-2024-financial-results-and-corporate-update/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-to-participate-in-fireside-chat-at-the-needham-virtual-healthcare-conference/ 2025-10-22 weekly 0.5 https://www.mereobiopharma.com/news/ultragenyx-and-mereo-biopharma-announce-ux143-phase-3-orbit-study-for-osteogenesis-imperfecta-progressing-to-final-analysis/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-second-quarter-2025-financial-results-and-provides-corporate-highlights/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-to-participate-in-fireside-chat-at-the-cantor-global-healthcare-conference/ 2025-11-13 weekly 0.5 https://www.mereobiopharma.com/news/mereo-to-participate-in-fireside-chat-at-the-jefferies-healthcare-conference-in-london/ 2026-03-10 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-third-quarter-2025-financial-results-and-provides-corporate-highlights/ 2025-11-20 weekly 0.5 https://www.mereobiopharma.com/news/phase-3-orbit-and-cosmic-results/ 2025-12-29 weekly 0.5 https://www.mereobiopharma.com/news/first-quarter-2024-financial-results/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-pricing-of-50-million-underwritten-registered-direct-offering-of-american-depository-shares-priced-at-the-market/ 2025-09-15 weekly 0.5 https://www.mereobiopharma.com/news/ultragenyx-and-mereo-biopharma-announce-new-phase-2-data-from-phase-23-orbit-study-demonstrating-sustained-reductions-in-fracture-rates-following-treatment-with-setrusumab-ux143-in-patients-with-osteogenesis-imperfecta-oi/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/corporate-update/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-full-year-2023-financial-results-and-provides-corporate-update/ 2025-12-11 weekly 0.5 https://www.mereobiopharma.com/news/completion-of-enrollment-in-phase-3-orbit-and-cosmic-studies/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/biotech-tv-interview/ 2025-05-21 weekly 0.5 https://www.mereobiopharma.com/news/second-quarter-2024-financial-results/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/breakthrough-therapy-designation/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/third-quarter-earnings/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/jefferies-june-conference/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-listing-transfer-to-nasdaq-capital-market/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/ats-congress-2023/ 2025-10-01 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/orbit-phase-2/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-full-year-2022-financial-results-and-recent-highlights/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/regulatory-updates-on-alvestat/ 2025-07-02 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-provides-regulatory-updates-on-alvelestat-for-the-treatment-of-alpha-1-antitrypsin-deficiency-associated-lung-disease/ 2025-10-02 weekly 0.5 https://www.mereobiopharma.com/news/notice-of-agm/ 2025-05-19 weekly 0.5 https://www.mereobiopharma.com/news/first-patient-dosing/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mid-year-financial-results/ 2025-10-21 weekly 0.5 https://www.mereobiopharma.com/news/corporate-update/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/asbmr-press-release/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-appointment-of-dr-abdul-mullick-to-board-of-directors/ 2025-09-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-positive-top-line-efficacy-and-safety-data-from-astraeus-phase-2-trial-of-alvelestat-in-alpha-1-antitrypsin-deficiency-associated-emphysema/ 2025-10-06 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-the-presentation-of-updated-data-from-a-phase-1b2-study-of-etigilimab-as-a-poster-at-the-2022-american-society-of-clinical-oncology-annual-meeting-2/ 2025-10-16 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-to-present-data-update-for-the-phase-1b2-study-activate-of-etigilimab-and-nivolumab-at-2022-asco-annual-meeting-mereo-also-updates-capital-allocation-and-portfolio-prioritization-plan-2/ 2025-10-06 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-appointment-of-anne-hyland-to-board-of-directors/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-full-year-2021-financial-results-and-recent-highlights/ 2025-10-06 weekly 0.5 https://www.mereobiopharma.com/news/mereos-partner-ultragenyx-announces-first-patient-dosed-in-pivotal-phase-23-study-of-setrusumab-ux143-for-the-treatment-of-osteogenesis-imperfecta/ 2025-10-06 weekly 0.5 https://www.mereobiopharma.com/news/navicixizumab-phase-1b-data-presented-in-journal-of-clinical-oncology/ 2025-10-06 weekly 0.5 https://www.mereobiopharma.com/news/notice-of-agm/ 2025-05-20 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement/ 2025-07-02 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-sends-letter-to-rubric-capital-management-1/ 2025-10-06 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-sends-letter-to-rubric-capital-management/ 2025-10-06 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-and-ultragenyx-to-present-setrusumab-data-update-at-asbmr/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-offered-to-settle-proxy-contest-with-rubric-capital-management-by-putting-rubric-principal-and-second-new-director-on-the-board/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-clinical-update-and-interim-biomarker-analysis-presented-at-esmo-2022/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-updated-operating-plan-to-maximize-shareholder-value/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-confirms-receipt-of-a-valid-notice-requiring-it-to-convene-a-general-meeting-of-shareholders-2/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-files-shareholder-circular-for-upcoming-general-meeting-2/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reaches-cooperation-agreement-with-rubric-capital-management/ 2025-10-03 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-receives-fda-fast-track-designation-for-alvelestat-for-treatment-of-alpha-1-antitrypsin-deficiency-aatd-associated-lung-disease/ 2025-10-02 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-positive-desmosine-biomarker-data-from-an-interim-analysis-of-an-investigator-initiated-study-of-alvelestat-in-bronchiolitis-obliterans-syndrome-bos/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-full-year-2020-financial-results-and-recent-highlights/ 2025-07-02 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-and-cancer-focus-fund-announce-partnership-for-phase-1b2-study-of-etigilimab-in-clear-cell-ovarian-cancer/ 2025-10-02 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-appointment-of-pierre-jacquet-md-phd-to-board-of-directors/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-and-ultragenyx-present-data-from-the-phase-2b-asteroid-study-of-ux143-setrusumab-in-osteogenesis-imperfecta-oi-at-the-american-society-for-bone-and-mineral-research-asbmr-2021-annual-meeting/ 2025-07-02 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-receives-us-orphan-drug-designation-for-alvelestat-in-the-treatment-of-alpha-1-antitrypsin-deficiency/ 2025-10-02 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-the-osteogenesis-imperfecta-federation-europe-oife-and-the-osteogenesis-imperfecta-foundation-oif-announces-completion-of-the-impact-survey-enrollment/ 2025-10-02 weekly 0.5 https://www.mereobiopharma.com/news/raising-awareness-around-alpha-1-antitrypsin-deficiency/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-interim-data-from-activate-phase-1b2-open-label-study-of-etigilimab-anti-tigit-antibody-in-combination-with-nivolumab-in-solid-tumors/ 2025-10-02 weekly 0.5 https://www.mereobiopharma.com/news/data-from-investigator-sponsored-trial-of-mereo-biopharma-s-alvelestat-in-bronchiolitis-obliterans-syndrome-bos-accepted-for-presentation-at-american-society-of-hematology-ash-annual-meeting/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/biomarker-data-from-phase-1b2-investigator-sponsored-trial-of-mereo-s-alvelestat-in-bronchiolitis-obliterans-syndrome-bos-at-the-ash-annual-meeting/ 2025-10-02 weekly 0.5 https://www.mereobiopharma.com/news/uab-and-mereo-announce-positive-top-line-results-from-costa-a-phase-1b2-trial-of-alvelestat-mph966-in-hospitalized-patients-with-covid-19-respiratory-disease/ 2025-07-02 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-strengthens-management-team-appoints-john-lewicki-phd-as-chief-scientific-officer-and-ann-kapoun-phd-as-svp-of-translational-research-and-development/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-financial-results-for-the-year-ended-december-31-2019/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-completion-of-70-million-private-placement/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-additional-positive-data-from-phase-2b-asteroid-study-of-setrusumab-in-adults-with-osteogenesis-imperfecta-and-provides-update-on-regulatory-progress/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-and-oncologie-enter-into-global-licensing-agreement-for-navicixizumab/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-positive-feedback-from-type-b-end-of-phase-2-meeting-with-the-fda-and-outlines-pivotal-phase-3-pediatric-study-design-for-setrusumab-in-osteogenesis-imperfecta/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-equity-investment-of-3-million-from-new-us-institutional-investor/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-update-on-distribution-related-to-contingent-value-rights-following-recent-oncologie-licensing-agreement-for-navicixizumab/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-enters-into-a-5-million-convertible-equity-financing-with-novartis-and-announces-a-securities-purchase-agreement-with-aspire-capital-fund-llc-for-up-to-28-million/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/business-update-and-directorate-change/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-initiation-of-placebo-controlled-phase-1b2-clinical-trial-with-alvelestat-in-covid-19-respiratory-disease/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-interim-financial-results-for-the-six-months-ended-june-30-2020-and-provides-corporate-update/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-receives-fda-rare-pediatric-disease-designation-for-setrusumab-for-the-treatment-of-osteogenesis-imperfecta/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-appoints-christine-fox-as-chief-financial-officer-and-heidi-petersen-as-senior-vice-president-regulatory-affairs/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-fda-clearance-to-proceed-into-a-phase-1b2-study-for-etigilimab-anti-tigit/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-appoints-suba-krishnan-md-as-senior-vice-president-of-clinical-development/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-and-ultragenyx-announce-collaboration-and-license-agreement-for-setrusumab-in-osteogenesis-imperfecta/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-provides-update-on-aim-delisting-and-continued-listing-of-its-adss-on-nasdaq-and-provides-update-on-agreements-with-silicon-valley-bank-and-kreos-capital/ 2025-10-31 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-group-plc-announces-positive-early-6-month-data-from-the-open-label-arm-of-the-phase-2b-clinical-study-in-adult-patients-with-type-i-iii-or-iv-osteogenesis-imperfecta-treated-with-the-anti-sclerostin-antibody-bps-804-setrusu/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-intention-to-purchase-shares-by-trustee-of-employee-benefit-trust/ 2025-10-20 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-update-on-etigilimab-tigit-partnership/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-publicly-files-registration-statement-on-form-f-4-with-us-securities-and-exchange-commission/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-to-announce-preliminary-results-for-the-full-year-2018-and-host-conference-call-on-april-29-2019/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-group-today-announces-that-in-connection-with-the-completed-merger-with-oncomed-pharmaceuticals-inc/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-completion-of-the-merger-with-oncomed-pharmaceuticals-inc/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-group-plc-mereo-or-the-company-or-the-group-merger-update-acquisition-of-oncomed-pharmaceuticals-inc-oncomed-result-of-oncomed-stockholder-meeting/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-appoints-richard-francis-as-head-of-pharmaceutical-development/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-successful-type-b-meeting-with-us-fda-and-outlines-accelerated-approval-pathway-for-navicixizumab-in-advanced-ovarian-cancer/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-setrusumab-6-month-phase-2b-data-in-osteogenesis-imperfecta-selected-for-late-breaking-oral-presentation-at-the-american-society-for-bone-and-mineral-research-asbmr-2019-annual-meeting/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-interim-financial-results-for-the-six-months-ended-june-30-2019-and-provides-corporate-update/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-to-announce-interim-financial-results-for-the-six-months-ended-june-30-2019-and-provide-corporate-update-on-september-17-2019/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-receives-fda-fast-track-designation-for-navicixizumab-for-the-treatment-of-heavily-pretreated-ovarian-cancer/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-s-setrusumab-demonstrates-dose-dependent-bone-building-and-trend-in-fracture-reduction-in-phase-2b-asteroid-study-in-adults-with-osteogenesis-imperfecta/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-first-patient-dosed-in-phase-2-alpha-1-antitrypsin-deficiency-study/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-positive-results-from-the-safety-extension-study-to-the-phase-2b-clinical-trial-of-bgs-649-for-the-treatment-of-hypogonadotropic-hypogonadism-in-obese-men/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-announces-agreement-with-astrazeneca-ab-astrazeneca-for-an-exclusive-license-and-option-to-acquire-azd9668/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-receives-ema-prime-designation-for-bps-804-to-treat-osteogenesis-imperfecta/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/mereo-announces-positive-top-line-results-from-phase-2-trial-with-bct-197-acumapimod/ 2025-10-30 weekly 0.5 https://www.mereobiopharma.com/news/jp-morgan-presentation/ 2026-01-14 weekly 0.5 https://www.mereobiopharma.com/news/mereo-provides-a-corporate-update/ 2026-01-14 weekly 0.5 https://www.mereobiopharma.com/news/mereo-biopharma-reports-full-year-2025-financial-results-and-provides-corporate-highlights/ 2026-03-19 weekly 0.5 https://www.mereobiopharma.com/about-us/ 2026-03-25 weekly 0.0 https://www.mereobiopharma.com/about-us/our-team/ 2026-01-12 weekly 0.5 https://www.mereobiopharma.com/about-us/join-us/ 2025-11-13 weekly 0.5 https://www.mereobiopharma.com/search/ 2025-06-24 weekly 0.5 https://www.mereobiopharma.com/privacy-notice/ 2025-09-17 weekly 0.5 https://www.mereobiopharma.com/privacy-notice/mereo-privacy-notice/ 2026-01-14 weekly 0.5 https://www.mereobiopharma.com/privacy-notice/recruitment-privacy-notice/ 2026-01-14 weekly 0.5 https://www.mereobiopharma.com/privacy-notice/vendor-privacy-notice/ 2026-01-14 weekly 0.5 https://www.mereobiopharma.com/privacy-notice/hcp-privacy-notice/ 2025-12-11 weekly 0.5 https://www.mereobiopharma.com/cookie-notice/ 2026-01-12 weekly 0.5